H.C. Wainwright Downgrades FibroGen (FGEN) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
FibroGen (FGEN) PT Lowered to $55 at Stifel
April 7, 2021 7:49 AM EDTStifel analyst Annabel Samimy lowered the price target on FibroGen (NASDAQ: FGEN) to $55.00 (from $70.00) while maintaining a Buy rating.
The analyst commented, "FGENs clarification of a different Roxadustat cardiovascular safety analysis is another unpleasant surprise, but it is not clear that it changes the... More
Mizuho Securities Downgrades FibroGen (FGEN) to Neutral
April 7, 2021 6:30 AM EDTMizuho Securities analyst Difei Yang downgraded FibroGen (NASDAQ: FGEN) from Buy to Neutral with a price target of $29.00.
The analyst comments "We are downgrading FGEN shares to Neutral, and reducing our PT from $72 to $29 as we see higher risk and uncertainty around timelines to... More
